Abstract
Background
Renal cell carcinoma (RCC) is a common cancer, accounting for about 2–3% of all adult cancers. A novel diagnostic biomarker and therapeutic target is urgently needed. However, the function of miR-451 in RCC remains unknown. Here, we explored the role of miR-451 in RCC.
Material/Methods
MiR-451 levels in RCC tissues and cells were tested by qRT-PCR. Cells were transfected miR-451 mimics or miR-451 ASO by Lipofectamine. The cellular proliferation was tested by MTT analysis. The apoptosis rate was revealed by FACS. Bioinformatics algorithms from TargetScanHuman were used to predict the target genes of miR-451. The PSMB8 protein level was tested by Western blot. The interaction between miR-451 and PSMB8 was confirmed by dual luciferase assays.
Results
MiR-451 level of RCC tissues was lower than in normal tissues, which was correlated to the patients’ survival rate. Low levels of miR-451 in RCC cells promoted the growth of cells and inhibited cells apoptosis and vice versa. The targeted gene of miR-451 is PSMB8.
Conclusions
MiR-451 acts as an anti-oncogene in RCC. Our data offer a new therapeutic target for further research.
MeSH Keywords: Apoptosis; Carcinoma, Renal Cell; Cell Proliferation; MicroRNAs
Background
Renal cell carcinoma (RCC) accounts for 2–3% of all malignant tumor in adults, whose incidence ranks seventh in men and ninth in women [1]. The most common renal cancer histology is clear cell RCC (ccRCC), which accounts for 70–80% of all RCC, characterized by loss of 3p in >90% of cases [2,3]. Early-stage ccRCC is potentially curable by surgery, although approximately 6% of patients newly diagnosed with RCC present with metastases [4]. The prognosis for metastatic ccRCC remains poor, with a 5-year survival rate <10%, although molecular-targeted drugs are currently administered for the treatment of metastatic ccRCC. This calls for urgent research into therapeutic approaches for RCC.
MicroRNAs (miRNAs) are a group of small non-coding RNAs that negatively regulate gene expression through inhibiting translation of messenger RNA (mRNA) or targeting mRNAs for degradation [5]. Currently, more than 1000 miRNAs have been identified in human cells, and these regulate an estimated 30% of all gene expression [6]. Aberrant miRNA expression is involved in tumorigenesis of several cancers, including ccRCC [7].
The role of miR-451 in bladder cancer was initially reported in 2014 [8] in a study reporting a low level of miR-451 in bladder cancer tissues, and in which miR-451 was shown to be a tumor-suppressing factor via epithelial mesenchymal transition. Another study indicated that miR-451 showed a strong correlation with progression-free survival of RCC patients [9]. Unfortunately, the exact role of miR-451 in RCC and the underlying mechanism remain unclear.
In this study, the role of miR-451 in RCC was the main focus. The effect of miR-451 on cellular proliferation and cell apoptosis and the potential targeted genes of miR-451 were researched. Our hope was to provide a description of miR-451 in RCC and a potential therapeutic target for further investigation.
Material and Methods
Patients and cancer tissues
We postoperatively acquired 51 RCC tissues and the corresponding peripheral normal tissues in 2011 from the Third People’s Hospital, Chengdu (Chengdu, China). All patients gave signed, informed consent for the use of their tissues for scientific research. Ethics approval for the study was obtained from the Ethics Committee/Institutional Review Board of Sichuan University (Chengdu, China). Diagnoses were made according to the pathological evidence by the senior pathologists of the Third People’s Hospital, using the specimens in accordance with the classification criteria of the WHO. RCC tissues were acquired prior to radiotherapy and chemotherapy, and were instantly stored at −80°C for subsequent analysis. All the RCC patients were followed for 36 months and a set of complete clinical data was recorded properly. The clinical information is provided in Supplementary Table 1.
Cell culture
Human renal caner cell lines ACHN, Caki-1, 786-O, A498, and HEK293T cells were purchased from the Cell Bank of Sichuan University (Chengdu, China). HEK293T was maintained in RPMI1640 with 10% fetal bovine serum (FBS) (Gibco BRL, Grand Island, NY, USA). ACHN, Caki-1, 786-O, and A498 were cultured in DMEM medium with 10% fetal bovine serum (Gibco BRL, Grand Island, NY).
MTT assay
Cells were seeded at a density of 5×103 cell per well in 96-well plates. After incubation for 48 h, 20 μl of 3,(4,5-dimethyl-2-thiazolyl) -2,5-diphenyl-2H-tetrazolium bromide (MTT) solution (5 mg/ml in PBS) was added to each well for 3 h at 37°C. Subsequently, a culture medium with MTT was removed and a 200 ll DMSO were added (Shanghai Sangon Biological Engineering Technology and Services Co., Ltd, Shanghai, China). Absorbance was read at 490 nm using a Universal Microplate Spectrophotometer (Bio-Tek Instruments, Inc., Winooski, VT). The data are expressed as percentage of growth relative to that of cells in the untreated group [10,11].
MiRNAs quantification
RNA was extracted by Trizol reagent (Invitrogen, CA) as standard method [12]. TaqMan miRNA assays (Applied Bio-systems, CA) were used for semiquantitative determination of the expression of miRNAs according to the manufacturer’s instructions. Briefly, 10 ng of total RNA was reverse transcribed using miRNA-specific stem-loop RT primers, MultiScribe reverse transcriptase, RT buffer, dNTPs, and RNase inhibitor (Applied Biosystems) in the GeneAmp 9700 PCR system (Applied Biosystems) under the following conditions: 16°C for 30 min, 42°C for 30 min, and 85°C for 5 min. Real-time PCR was performed on the resulting complementary DNA (cDNA) using miRNA-specific TaqMan primers and TaqMan Universal PCR Master Mix in a 7500 real-time PCR system (Applied Biosystems) with the following conditions: 95°C for 10 min followed by 40 cycles of 95°C for 15 s and 60°C for 1 min [13]. The relative expression was normalized to the expression of U6 (Applied Biosystems). Relative fold changes of gene expression were calculated by the ΔΔCT method [14] and the values are expressed as 2−ΔΔCT.
MiRNA transfection
MiR-451 mimics and miR-451 antisense oligonucleotides (miR-451 ASO) and the miRNA mimics negative control were purchased from Ambion (Ambion Life Technologies, Austin, TX). ACHN, Caki-1, 786-O, and A498 cells were seeded into 24-well plates and then transfected with miR-451 mimics or miR-451 ASO by Lipofectamine (Invitrogen, Shanghai, China), according to the manufacturer’s instructions [15].
Apoptosis assay for flow cytometry
Cells were harvested and washed with PBS 3 times. The Fc receptor was blocked by 3% fetal bovine albumin. Cells were stained with FITC-labeled annexin-V antibody for 20 min. Before analyzing by FACS, PI was added.
Western blot
The proteins of cell were separated by electrophoresis and then were transfer to PVDF filter membranes. The PVDF membranes were then incubated with blocking buffer (TBST, 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween-20, 50% skimmed milk) for 1 h at room temperature, followed by overnight treatment with the primary antibody at 4°C, and then with an HRP-conjugated secondary antibody. The reactive bands were detected by ECL after washing. Antibodies used in this experiment were rabbit polyclonal anti-PSMB8 (sc-134503) and anti-β-actin from Santa Cruz Antibodies (Santa Cruz, CA).
MicroRNAs targets prediction
The online software TargetScanHuman [16–19] was used to predict the potential targeted genes of miR-451.
PSMB8 3′UTR reporter analysis
Luciferase assays were performed according to the manufacturer’s protocol. We seeded 293T cells into 96-well plates at a density of 6×104 per well. The mutations in the miR-451 seed regions of the PSMB8 3′UTR were generated using the QuikChange Multi site-directed mutagenesis kit (Promega, Fitchburg, WI). RL reporter plasmids (3.6 fmol) and pGL3-control (500 ng for normalization) (Promega, Fitchburg, WI) were transfected with Lipofectamine 2000 (Invitrogen, Canada) into cells. Cells were collected after 48 h for assay using the Dual Luciferase reporter assay system (Promega, Fitchburg, WI) [20,21].
Statistical analysis
All statistical tests were performed using SPSS software (SPSS, Chicago, IL). Overall survival of patients was estimated by the Kaplan-Meier method. The two-tailed Student’s t test was used to analyze the difference between 2 groups and ANOVA was used to analyze the difference between 3 groups. The differences in expression of miR-451 between RCC tissues and corresponding normal tissues were tested by the Wilcoxon matched-pairs signed rank test. Correlation analysis was performed by two-tailed Person’s correlation coefficient analysis. Differences were considered statistically significant when the p value was less than 0.05.
Results
Down-regulation of miR-451 was correlated with lower survival rate of RCC patients
To study the role of miR-451 in RCC, we initially tested the miR-451 expression in RCC tissues by qRT-PCR. The relative miR-451 level in RCC tissue and the corresponding tumor-adjacent normal tissues were compared. The research showed that in all 51 pairs, there were only 5 pairs with higher levels of miR-451 in RCC tissues (Figure 1A). Significantly, the miR-451 mean level of all RCC was lower than mean level in normal tissues (Figure 1B). By using Kaplan-Meyer analysis, we showed that the low expression of miR-451 was correlated with lower patient survival rate (Figure 1C).
Up-regulation of miR-451 inhibited the growth of RCC cells and induced apoptosis of cells
Next, we examined the miR-451 levels in RCC cell lines by qRT-PCR, and we found that, compared with normal renal tissues, the miR-451 level was decreased in RCC cells (Figure 2A). Because miR-451 levels in Caki-1 and 786-O cells appeared to be lower than in other RCC cells, the Caki-1 and 786-O cells were transfected with miR-451 mimics. At 48 h using after transfection, the miR-451 levels in Caki-1 and 786-O cells were assayed by qRT-PCR. We found that miR-451 levels in Caki-1 and 786-O cells were overexpressed by miR-451 mimics transfection (Figure 2B). Subsequently, cell growth was examined by MTT analysis, showing that miR-451 mimics transfection suppressed the growth of Caki-1 and 786-O cells (Figure 2C). Next, the apoptosis rate of these cells were tested by FACS apoptosis analysis, and data showed that up-regulation of miR-451 promoted cell apoptosis in Caki-1 and 786-O cells (Figure 2D).
Inhibition of miR-451 promoted the proliferation of RCC cells and inhibited cell apoptosis
ACHN and A498 cells showed higher levels of miR-451 than other cells; therefore, we down-regulated the miR-451 levels in ACHN and A498 cells by transfecting them with miR-451 ASO. The miR-451 levels were assayed by qRT-PCR (Figure 3A). Then the cells growth was assayed by MTT analysis and data showed that miR-451 ASO transfection favored the growth of ACHN and A498 cells (Figure 3B). Next, 48 h following the miR-451 ASO transfection, we examined the cell apoptosis by FACS analysis. These data showed that down-regulation of miR-451 decreased the cell apoptosis rate (Figure 3C).
The PSMB8 gene was targeted by miR-451
To research the targeted genes of miR-451, bioinformatics methods were used. We found that the PSMB8 gene is one of the targeted genes of miR-451. The binding site and the mutated version are depicted in Figure 4A. The intact 3′UTR of PSMB8 and its mutated version were cloned into luciferase reporter plasmids that were then used for co-transfection with miR-451 into 293T cells. We discovered that the transcripts carrying the PSMB8 3′UTR exhibited a significant reduction in luciferase activity in the presence of miR-451. In contrast, the control had no significant effect on the luciferase activity (P>0.05) (Figure 4B). At 48 h after miR-451 mimics transfection, the PSMB8 protein level in Caki-1 cells were assayed by Western blot, and we found that overexpression of miR-451 inhibited the PSMB8 protein level in Caki-1 cells (Figure 4C). Finally, the PSMB8 mRNA levels and miR-451 levels in 9 RCC samples were assayed by qRT-PCR, and data showed that there is a negative correlation between PSMB8 mRNA levels and miR-451 levels (Figure 4D).
Discussion
Here, we researched the function of miR-451 in RCC. We discovered that the RCC tissues showed a lower level of miR-451, and the low expression of miR-451 was correlated with lower patient survival rate. Low level of miR-451 in RCC cells may promote the growth of cells and vice versa. The targeted gene of miR-451 is PSMB8.
To the best of our best knowledge, this is the first report of miR-451 in RCC. MiR-451 has been investigated in a previous study [22] reporting that up-regulation of miR-451 suppressed the proliferation, invasion, and metastasis of A549 lung cancer cells. The inflammation-related gene PSMB8 is a target for miR-451. Our data showed a similar role of miR-451 in RCC.
Interestingly, PSMB8 has been proven to be involved in inflammatory disease. Research has shown that PSMB8 influenced the intensity of NF-κB-mediated inflammation in inflammatory bowel disease [23,24] and caused auto-inflammatory disorder [25]. PSMB8 knockout mice developed significantly attenuated colitis and had limited secretion of proinflammatory cytokines and chemokines [26]. Inhibition of PSMB8 can block cytokine production and attenuates progression of experimental arthritis [27].
Previous studies suggest that inflammation plays important roles in RCC [28], including a prognostic role [29]. Our data suggest that inflammation influences the development of cancer via PSMB8, which is regulated by miR-451.
MiR-451 also plays roles in inflammation-related diseases. For example, in rheumatoid arthritis, miR-451 suppresses neutrophil chemotaxis via p38 MAPK pathways [30]. Thus, we hypothesized that miR-451 may play a role in RCC via a pathway of inflammation.
Conclusions
Our data revealed the role of miR-451 in RCC. We found that the down-regulation of miR-451 was correlated with lower survival rate of RCC patients, and that overexpression of miR-451 inhibits the proliferation of RCC cells and vice versa. The targeted gene of miR-451 is PSMB8. We hope our study provides a new therapeutic target in RCC.
Supplementary materials
Supplementary Table 1.
Variables | Values, mean ±SD |
---|---|
Gender | |
Male | 24 |
Female | 27 |
Age at diagnosis | 59.3±14.5 |
Tumor stage | |
T1–T2 | 26 |
T3–T4 | 15 |
Cell type | |
Clear cell | 51 |
Chromophobe | 0 |
Overall follow-up (days) | |
Mean | 1421 |
Median | 1572 |
Range | 342–2500 |
Footnotes
Source of support: Departmental sources
Disclosure statement
The authors have declared that no competing interests exist.
References
- 1.Gupta K, Miller JD, Li JZ, et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev. 2008l;34:193–205. doi: 10.1016/j.ctrv.2007.12.001. [DOI] [PubMed] [Google Scholar]
- 2.Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373:1119–32. doi: 10.1016/S0140-6736(09)60229-4. [DOI] [PubMed] [Google Scholar]
- 3.van den Berg E, Dijkhuizen T. Classification of renal cell cancer based on (cyto)genetic analysis. Contributions Nephrol. 1999;128:51–61. doi: 10.1159/000059979. [DOI] [PubMed] [Google Scholar]
- 4.Novara G, Ficarra V, Antonelli A, et al. Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: Are further improvements needed? Eur Urol. 2010;58:588–95. doi: 10.1016/j.eururo.2010.07.006. [DOI] [PubMed] [Google Scholar]
- 5.Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–33. doi: 10.1016/j.cell.2009.01.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight? Nat Rev Gen. 2009;9:102–14. doi: 10.1038/nrg2290. [DOI] [PubMed] [Google Scholar]
- 7.Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–66. doi: 10.1038/nrc1997. [DOI] [PubMed] [Google Scholar]
- 8.Zeng T, Peng L, Chao C, et al. miR-451 inhibits invasion and proliferation of bladder cancer by regulating EMT. Int J Clin Exp Pathol. 2014;7(11):7653–62. [PMC free article] [PubMed] [Google Scholar]
- 9.Heinzelmann J, Henning B, Sanjmyatav J, et al. Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol. 2011;29:367–73. doi: 10.1007/s00345-010-0633-4. [DOI] [PubMed] [Google Scholar]
- 10.Wang G, Mao W, Zheng S, Ye J. Epidermal growth factor receptor-regulated miR-125a-5p – a metastatic inhibitor of lung cancer. FEBS J. 2009;276:5571–78. doi: 10.1111/j.1742-4658.2009.07238.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Yildirim V, Doganci S, Yesildal F, et al. Sodium nitrite provides angiogenic and proliferative effects in vivo and in vitro. Med Sci Monit Basic Res. 2015;21:41–46. doi: 10.12659/MSMBR.893727. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Min W, Wang B, Li J, et al. The expression and significance of five types of miRNAs in breast cancer. Med Sci Monit Basic Res. 2014;20:97–104. doi: 10.12659/MSMBR.891246. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.He XY, Chen JX, Zhang Z, et al. The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice. J Cancer Res Clin Oncol. 2010;136:1023–28. doi: 10.1007/s00432-009-0747-5. [DOI] [PubMed] [Google Scholar]
- 14.Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–8. doi: 10.1006/meth.2001.1262. [DOI] [PubMed] [Google Scholar]
- 15.Song B, Zhang C, Li G, et al. MiR-940 inhibited pancreatic ductal adenocarcinoma growth by targeting MyD88. Cell Physiol Biochem. 2015;35:1167–77. doi: 10.1159/000373941. [DOI] [PubMed] [Google Scholar]
- 16.Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15–20. doi: 10.1016/j.cell.2004.12.035. [DOI] [PubMed] [Google Scholar]
- 17.Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19:92–105. doi: 10.1101/gr.082701.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Grimson A, Farh KK, Johnston WK, et al. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell. 2007;27:91–105. doi: 10.1016/j.molcel.2007.06.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Garcia DM, Baek D, Shin C, et al. Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs. Nat Struct Mol Biol. 2011;18:1139–46. doi: 10.1038/nsmb.2115. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Grentzmann G, Ingram JA, Kelly PJ, et al. A dual-luciferase reporter system for studying recoding signals. RNA. 1998;4:479–86. [PMC free article] [PubMed] [Google Scholar]
- 21.Yuan B, Liang Y, Wang D, Luo F. MiR-940 inhibits hepatocellular carcinoma growth and correlates with prognosis of hepatocellular carcinoma patients. Cancer Sci. 2015;106:819–24. doi: 10.1111/cas.12688. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Yin P, Peng R, Peng H, et al. MiR-451 suppresses cell proliferation and metastasis in A549 lung cancer cells. Mol Biotechnol. 2015;57:1–11. doi: 10.1007/s12033-014-9796-3. [DOI] [PubMed] [Google Scholar]
- 23.Visekruna A, Joeris T, Schmidt N, et al. Comparative expression analysis and characterization of 20S proteasomes in human intestinal tissues: The proteasome pattern as diagnostic tool for IBD patients. Inflamm Bowel Dis. 2009;15:526–33. doi: 10.1002/ibd.20805. [DOI] [PubMed] [Google Scholar]
- 24.Visekruna A, Joeris T, Seidel D, et al. Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis. J Clin Invest. 2006;116:3195–203. doi: 10.1172/JCI28804. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Arima K, Kinoshita A, Mishima H, et al. Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc Natl Acad Sci USA. 2011;108:14914–19. doi: 10.1073/pnas.1106015108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Schmidt N, Gonzalez E, Visekruna A, et al. Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis. Gut. 2010;59:896–906. doi: 10.1136/gut.2009.203554. [DOI] [PubMed] [Google Scholar]
- 27.Muchamuel T, Basler M, Aujay MA, et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med. 2009;15:781–87. doi: 10.1038/nm.1978. [DOI] [PubMed] [Google Scholar]
- 28.de Vivar Chevez AR, Finke J, Bukowski R. The role of inflammation in kidney cancer. Adv Exp Med Biol. 2014;816:197–234. doi: 10.1007/978-3-0348-0837-8_9. [DOI] [PubMed] [Google Scholar]
- 29.Wu Y, Fu X, Zhu X, et al. Prognostic role of systemic inflammatory response in renal cell carcinoma: A systematic review and meta-analysis. J Cancer Res Clin Oncol. 2011;137:887–96. doi: 10.1007/s00432-010-0951-3. [DOI] [PubMed] [Google Scholar]
- 30.Murata K, Yoshitomi H, Furu M, et al. MicroRNA-451 down-regulates neutrophil chemotaxis via p38 MAPK. Arthritis Rheumatol. 2014;66:549–59. doi: 10.1002/art.38269. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Supplementary Table 1.
Variables | Values, mean ±SD |
---|---|
Gender | |
Male | 24 |
Female | 27 |
Age at diagnosis | 59.3±14.5 |
Tumor stage | |
T1–T2 | 26 |
T3–T4 | 15 |
Cell type | |
Clear cell | 51 |
Chromophobe | 0 |
Overall follow-up (days) | |
Mean | 1421 |
Median | 1572 |
Range | 342–2500 |